Phase II study shows oral tazarotene treatment yields QOL benefits for sufferers of severe acne


Washington D.C. ?? Patients with severe nodulocystic acne treated with oral tazarotene experience a substantial improvement in acne-specific health-related quality of life (HRQOL), according to the results of a Phase II dose-ranging study presented by Patricia S. Walker, M.D., Ph.D., at the annual meeting of the American Academy of Dermatology.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.